Showing results (131-140 of 222) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
JNCI Cancer Spectrum|April 5, 2019
The Epidemiology of Cancer Among Homeless Adults in Metropolitan DetroitAndreana N Holowatyj, Elisabeth I Heath, Lisa M Pappas, et al.
Investigational New Drugs|February 7, 2019
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancerDeaglan McHugh, Mario Eisenberger, Elisabeth I Heath, et al.
JAMA Oncology|September 17, 2020
Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate CancerNicole Senft, Lauren M Hamel, Mark A Manning, et al.
JAMA Network Open|January 26, 2021
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical TrialUlka N Vaishampayan, Lance K Heilbrun, Paul Monk, et al.
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2020
Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With EnzalutamideChristos E Kyriakopoulos, Elisabeth I Heath, Anna Ferrari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
CA: a Cancer Journal for Clinicians|May 23, 2019
The current state of molecular testing in the treatment of patients with solid tumors, 2019Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, et al.
Theranostics|May 8, 2023
Selective ablation of TRA-1-60<sup>+</sup> pluripotent stem cells suppresses tumor growth of prostate cancerJordan M White, Nicholas Ramos, Allen-Dexter Saliganan, et al.
Pageof 23